How Tirzepatide Works: The Dual GIP/GLP-1 Mechanism Behind Mounjaro

Tirzepatide is the first FDA-approved dual GIP and GLP-1 receptor agonist. Here is what that actually means, and why it matters for people managing type 2 diabetes or obesity.

When the FDA approved tirzepatide in May 2022 under the brand name Mounjaro, the press coverage focused mostly on weight loss numbers. The clinical data was genuinely striking. But the real story is in the pharmacology. Tirzepatide is not just another GLP-1 drug. It is the first medication to activate two incretin receptors simultaneously, and that distinction has significant clinical consequences.

The Incretin System, Briefly

Your gut releases hormones in response to food. Two of the most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, they account for roughly 50 to 70 percent of the insulin your body secretes after a meal, a phenomenon known as the incretin effect.

In type 2 diabetes, the incretin effect is blunted. The hormones are still released, but the body's response to them is diminished. Medications that mimic or enhance these hormones can help restore that response.

GLP-1: The Receptor Everyone Knows

GLP-1 receptor agonists have been available since exenatide (Byetta) was approved in 2005. The class includes liraglutide (Victoza), dulaglutide (Trulicity), and semaglutide (Ozempic). These drugs all work by binding to the GLP-1 receptor, which triggers several effects:

• Glucose-dependent insulin secretion. The pancreatic beta cells release more insulin, but only when blood sugar is elevated. This is why GLP-1 drugs carry a lower hypoglycemia risk than sulfonylureas or insulin when used alone.
• Glucagon suppression. Alpha cells in the pancreas reduce glucagon output, which lowers hepatic glucose production.
• Delayed gastric emptying. Food moves from the stomach to the small intestine more slowly, which blunts postprandial glucose spikes and contributes to reduced appetite.
• Central appetite regulation. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signals.

These drugs work well. Semaglutide, for instance, demonstrated A1C reductions of 1.5 to 1.8 percent in the SUSTAIN trials. But researchers at Eli Lilly hypothesized they could do better by adding a second target.

GIP: The Overlooked Partner

GIP was actually discovered before GLP-1. It was the first incretin hormone identified, back in the 1970s. But for decades, it was largely ignored by drug developers because studies showed that GIP's effect on insulin secretion was diminished in people with type 2 diabetes.

The thinking was straightforward: if the receptor does not respond well in diabetic patients, why target it? This assumption turned out to be incomplete.

More recent research has shown that GIP receptor activation does several things that GLP-1 alone does not do efficiently:

• Enhanced beta cell sensitivity. GIP appears to improve the beta cell's responsiveness to glucose over time, potentially through different intracellular signaling pathways than GLP-1.
• Fat tissue effects. GIP receptors are expressed on adipocytes (fat cells). Activation appears to influence lipid metabolism and may improve the body's ability to handle dietary fat.
• Reduced nausea. While GLP-1 agonists commonly cause nausea through delayed gastric emptying, some preclinical evidence suggests GIP signaling may partially counteract this effect, though the clinical data is mixed.
• Glucagon regulation. Unlike GLP-1, which suppresses glucagon, GIP can stimulate glucagon release when blood sugar is low. This may provide a counterregulatory safety mechanism against hypoglycemia.

Tirzepatide: Putting Both Together

Tirzepatide is a 39-amino-acid peptide engineered to activate both the GIP and GLP-1 receptors. It is not a simple combination of two drugs. It is a single molecule designed with greater affinity for the GIP receptor (about fivefold relative to native GIP) and somewhat lower but still significant affinity for the GLP-1 receptor.

The molecule also includes a C20 fatty diacid moiety that allows it to bind to albumin in the bloodstream, extending its half-life to approximately five days. This is what enables once-weekly dosing.

What the Clinical Trials Show

The SURPASS clinical trial program evaluated tirzepatide in over 20,000 adults with type 2 diabetes across multiple phase 3 studies. The results were consistently strong.

In SURPASS-2, which compared tirzepatide directly against semaglutide 1 mg, tirzepatide at all three doses (5 mg, 10 mg, and 15 mg) achieved greater A1C reductions and more weight loss than semaglutide. At the 15 mg dose, patients saw an average A1C reduction of 2.46 percent compared to 1.86 percent with semaglutide. Mean weight loss was 12.4 kg (27.3 lbs) versus 6.2 kg (13.7 lbs). These results were published in the New England Journal of Medicine in 2021.

The SURMOUNT trials evaluated tirzepatide specifically for weight management in people with obesity (without diabetes). SURMOUNT-1 showed an average weight reduction of 22.5 percent at the 15 mg dose over 72 weeks, published in the New England Journal of Medicine in July 2022. This was the largest weight reduction demonstrated by any anti-obesity medication in a major clinical trial at that time.

Why Dual Agonism Matters Clinically

The clinical relevance of targeting both receptors goes beyond the headline numbers. A few observations from the trial data:

Greater insulin sensitivity improvement. In SURPASS-3, tirzepatide improved markers of insulin sensitivity (measured by HOMA-IR) more than insulin degludec, suggesting effects that go beyond simply increasing insulin secretion. The drug appears to address insulin resistance itself, not just compensate for it.

Lipid improvements. Tirzepatide consistently reduced triglycerides by 19 to 25 percent across the SURPASS program, with modest improvements in LDL cholesterol and more meaningful increases in HDL. These effects likely relate partly to GIP's role in lipid metabolism.

Liver fat reduction. Early data from substudies suggest significant reductions in hepatic steatosis (fatty liver), which is common in type 2 diabetes and contributes to metabolic dysfunction.

Limitations and Open Questions

Dual agonism does not solve every problem. A few areas where uncertainty remains:

• Cardiovascular outcomes. The SURPASS-CVOT trial (evaluating cardiovascular outcomes) has been completed, but long-term data beyond a few years is still limited. Semaglutide has demonstrated cardiovascular benefit in the SELECT trial. Whether tirzepatide's dual mechanism provides additional cardiovascular protection is still being studied.
• Weight regain. SURMOUNT-4 showed that patients who stopped tirzepatide regained approximately two-thirds of the weight they had lost over the following year. This is consistent with other anti-obesity medications and underscores that these drugs manage, rather than cure, obesity.
• The GIP debate. Some researchers remain skeptical about GIP's contribution. A competing theory suggests that tirzepatide's benefits come primarily from its potent GLP-1 activity, and that the GIP component is less important than Lilly's data suggests. This is an active area of research.

The Bottom Line

Tirzepatide represents a genuine pharmacological advance. By targeting both the GIP and GLP-1 receptors, it achieves greater glycemic control and weight loss than any single-receptor agonist currently available. The SURPASS and SURMOUNT programs provide robust evidence for its efficacy.

Whether the dual mechanism also translates into long-term benefits for cardiovascular disease, fatty liver, or other metabolic complications remains to be fully established. But the mechanistic rationale is sound, and the clinical data so far is compelling.

As with any medication, the decision to use tirzepatide should be made with a healthcare provider who can evaluate your specific medical history, current medications, and treatment goals.